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The World Health Organization recently reported that breast cancer has become the most com-
mon cancer in women throughout theworld. Known risk factors account forless than halfofall
cases ofbreast cancer, and inherited germ line mutations occur in at most only 10% ofall cases.
Cumulative exposure to estradiol and other hormones link many ofthe established risk factors
forbreast cancer. This paper reviews epidemiologic andtoxicologicevidence on breast cancerrisks
and presents a comprehensive construct ofrisk factors intended to focus on the identification of
those factors that can be controlled or modified. We attempt to provide a framework for inter-
pretingtheetiologic interplayofendogenous metabolic changes andenvironmental changes inthe
etiology ofbreast cancer. The construct we develop distinguishes between those risk factors that
are directly causal, such as ionizing radiaton and inherited germ cell defects, those vulnerabdity
factors that extend the time period during which the breast undergoes development, and those
contributing factors that increase total hormonal stimulation ofthe breast. Some hormonally
active compounds, such as those in soy and broccoli and other phytoesogen-containing foods,
can be protective against breast cancer, while others, such as some environmental contaminants,
appear to increae the risk of the disee by increasing levels ofharmfud hormones. Efforts to
explain patterns of breast cancer should distinguish between these different risk factors.
Identification ofvulnerability and contributing risk factors can foster the development ofpublic
policy toreduce theburden ofthis prevaent cancer. Prdent preautionaryprinciples sugest that
reducing exposure to avoidable or modifiable risk factors should receiver high priority from the
public and private sectors. Key words. breast cancer, environment, hormones, prevention, riskfac-
tors, theory. EnvironHeal PenPect106:523-529 (1998). [Online 17August 1998]
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The World Health Organization recently
reported that breast cancer has become the
most common cancer in women through-
out the world (1-3). The causes of this
global pattern are not well understood. In
those few countries where mammographic
screening is routinely available, such as the
United States and some provinces of
Canada, increased ascertainment accounts
for some of the recorded increase in inci-
dence. In the United States recently,
declines in breast cancer mortality have
been reported for white and African-
American women under 65 years of age
(4). But changes in known risk factors,
diagnostic procedures, or aging cannot
account for domestic and worldwide pat-
terns in breast cancer incidence and mor-
tality. From 1973 to 1987, when routine
population mammographic screening was
not yet practiced, age-adjusted mortality
increased in both developed and develop-
ing countries (see Fig. 1 and 2). During
this period, breast cancer mortality grew
20% or more in several central European
countries and Japan, with rates of breast
cancer being about four times lower in
most Asian countries.
Established Risk Factors for
Breast Cancer
Less than 10% ofall breast cancer develops
in women who have inherited germ cell
mutations such as loss of tumor-suppressor
genes including p53, BRCA1, BRCA2, or
ATM (5,6). Established risk factors, which
have been identified in less than half of all
women with breast cancer (0, include inher-
ited genetic defects, menarche before age 12,
menopause after age 55, having either no
pregnancy or late childbearing, no lactation,
early or repeated exposures to radiation, pro-
longed use ofhormone replacement therapy,
increased breast density, higher socioeco-
nomic status, and postmenopausal obesity.
Most ofthese risk factors can be linked with
increased lifetime exposure to estrogen, other
hormones, and higher exposures early in life
(8-11). Most ofthese risk factors are not eas-
ily modifiable (12). Breast development
depends on the complex interplay of estro-
gen, progesterone, and other growth factors.
Therefore, the earlier in life that regular
menses begins and the later that it ceases, the
greater exposure to hormones that affect
breast growth in awoman's life (13).
Risk Factors
In an effort to identify public policies that
can be developed to reduce breast cancer, this
paper distinguishes between risk factors that
directly cause breast cancer, those that extend
the time period ofvulnerability ofthe breast
by prolonging breast development and conse-
quent susceptibility to damage, and those
that contribute to altered levels of cancer-
causing endogenous or xenohormones. What
exactly do these demonstrated risk factors for
breast cancer tell us? In fact, with the notable
exceptions ofionizing radiation and inherited
genetic damage, none of the established risk
factors for breast cancer directly causes the
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The Precautionary Principle
We must act on facts, and on the most accurate
interpretation of them, using the best scientific
information. That does not mean we must sit
back until we have 100% evidence about every-
thing. Where the state ofthe health ofthe people
is at stake, the risks can be so high and the costs
of corrective action so great, that prevention is
better than cure. We must analyze the possible
benefits and costs ofaction and inaction. Where
there are significant risks ofdamage to the pub-
lic health, we should be prepared to take action
to diminish those risks even when the scientific
knowledge is not conclusive, if the balance of
likely costs and benefits justifies it.
[Horton R TheNew New Public Health of
Risk andRadicalEngagement (editorial).
Lancet352(9124):251 (1998).]
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disease (14). Radiation and inherited defects
can besaid to causebreast cancer in thatthey
produce alterations in cell growth, repair,
and metabolism that are understood to be
mechanistically linked with the development
ofbreast cancer. According to accepted epi-
demiological criteria, risk factors can be
extracted from studies that consistently
reveal an association between certain condi-
tions that precede the development ofbreast
cancer (15). Even where such criteria are
met, a fundamental question must be
answered: Is the association between these
risk factors and the disease due to some
direct mechanism or causal link? Outside of
pharmaceutical and other medical interven-
tions such as diagnostic radiation, which are
studied under controlled conditions, few
human exposures can be directlylinked with
specific health consequences.
A variety of studies indicate that the
potential for aberrant growth is dependent
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which occur when breasts are undergoing
rapid cell differentiation, cell growth, or
development of the whole gland during
puberty could also be especially important
causes ofbreast cancer.
Vulnerability Factors
More rapidly developing cells, such as
those of the prepubescent breast, are at a
special state ofvulnerability. Vulnerability
factors for breast cancer are those that
extend the time during which the breast is
growing and the rate of this growth. For
instance, early menses, no lactation, and
late menopause prolong the time period
during which the developing breast is
potentially exposed to estradiol and delete-
rious agents (see Fig. 3). Evidence for this
increased vulnerability is provided by
,d countries, 1973-1987. Data from the observations of women born to mothers
who had unusually high or low levels of
estrogen during pregnancy. Toxemia is tied
with preeclampsia and lower levels ofestro-
gen. Women born to mothers who were
toxemic had an adjusted odds ratio (OR)
of0.41 for breast cancer compared to those
who underwent normal pregnancy. In con-
trast, women whoexperienced elevated lev-
M11_ els of hormones prenatally or neonatally
were found to have an ORof3.96 (18).
Regarding the risk factor of lactation,
the situation is complex. Lactation is a
potentially modifiable factor that can be
considered as both a vulnerability and a
contributing risk. Premenopausal women
who lactated have a reduced risk of breast
cancer, with further significant reductions
ofrisk for women who lactate earlier or for
longer cumulative duration. Animal studies
ig countries, 1973-1987. Data from the have demonstrated that early reproductive
life breast tissue is positively influenced by
lactation (19). Immediately before and
actors: the rate ofcell growth and after the termination of pregnancy, the
t ofexposure (16). Even for ioniz- rapidly growing or lactating breast may also
tion, the same dose can produce be at risk from proliferative processes and
ial responses depending upon the agents. After lactation ends, the breast
if exposure. Studies have consis- becomes more differentiated, reducing sus-
infirmed that females exposed to ceptibility to such agents (20). However,
i prior to puberty have a much postmenopausal women who have lactated
isk of developing breast cancer do not show reduced risk of breast cancer
older women subject to the same in comparison to women who have not lac-
!xposure (Se. tated (19). This may reflect the fact that
e findings about radiation and cumulative exposures to other cancer-caus-
ancer highlight a profoundly ing xenohormones overwhelm any earlier
lt component of risk factors for protective effects from lactation.
diseases with long latency: timing ofexpo-
sure can be more important than dose.
Radiation during the critical periods when
breast cells are first forming prenatally or
during early adolescence induces propor-
tionally more neoplastic transformation of
cells and is thereby more carcinogenic than
exposures that occur later in life (17). This
suggests that other carcinogenic exposures
Contributing Factors
Contributing factors can directly affect over-
all exposure to circulating hormones and can
interactwithvulnerability factors. Some hor-
mones are potent stimulators ofcell growth
(21), and some hormonal metabolites can
bind to DNA and trigger aberrant cell
growth (22,23). Alcohol, lack of exercise,
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diets low in fiber and vitamin D, and expo- cells, making them
sure to some pesticides, solvents, fuels, and quent exposures. W]
pharmaceuticals increase the total amount of ulating agents, ti
bioavailable estradiol (20). Bioavailable estra- respond more quick
diol represents the fraction ofestradiol that is growth renders tissui
not readily excreted when bound to sex hor- to carcinogens or]
mone-binding globulin (SHBG) or albumin pounds. In a simila
(24). This binding reduces the availability of exposures can exped
estradiol to the cells. Thus, processes that breast growth and
decrease hormone binding increase circulat- More rapidly develc
ing levels of estradiol. Contributing factors to sustainingaberrar
can also alter metabolism of other growth- anisms can be swar
regulating hormones that alter breast cell menses or obesity a
growth and metabolism and increase the cumulative exposur
likelihood ofaberrant cell growth. lites as adipose cells
Alcohol is a prime example ofa riskfac- gens. Thus, exposui
tor that may increase the circulation ofhor- can alter both the l
mones, thereby rendering it a contributing hormonal stimulatic
risk factor. A large nurses' health study
(25), later corroborated by a women's Role of Horm
health study (26), determined that post- Clinical and animal
menopausal women who consumed alcohol lifetime exposure to
manifested a 40% increased risk of breast estradiol predicts
cancer with estrogen administration, while (31,32). Under on
those who did not consume alcohol or con- alter hormonal meta
sumed it at levels below the average daily of breast cancer w
intake of 5 g showed no increased risk. and/or hormonal pa
When alcohol interacts with estrogen, the paths to breast can(
bioavailable estradiol level rises sharply indicates that differe
above breast cancer-promoting levels for ol oxidation have F
women in general (27). Another explana- logical effects (see
tion as to why regular consumption of humans is hydroxyl
alcohol increases breast cancer likelihood is irreversible and m
because ethanol is directly estrogenic (28). ways-16 a-hydro)
When additional direct risk factors, such as
inherited genetic mutations and p53 genes
(29) are taken into account, the effects of
alcohol are magnified (30).
Critical Windows of Exposure
Under this emerging paradigm, three distinct
critical windows need to be considered: pre-
natal, prepubescent, and perimenopausal.
Prenatal exposure to elevated levels ofestradi-
ol or other growth-regulating hormones
throughout gestation may imprint breast
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Figure 3. Risk factors can be distinguished in terms of their ability to cause
breast cancer directly, through genetic damage, or by altering hormonal
metabolism. Vulnerability factors prolong the duration of breast cell growth,
while contributing factors can distort hormone levels.
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profoundly different bio-
Fig. 4) (34). Estrone in
lated to form one or two
Lutually exclusive path-
xyestrone (16-OHEI) or
2-hydroxyestrone (2-OHE1) (35). The for-
mer metabolite appears to bind covalently to
the estrogen receptor (ER), while the latter
stimulates cell repair and inhibits cancer.
Another estradiol metabolite, 4-hydroxye-
strone (4-OHEI), also appears highly car-
cinogenic, although its significance for
humans is not clear (22). Two distinct mech-
anisms can influence the potential for aber-
rant cell growth: materials can directly bind
with hormone receptors altering cell prolifer-
ation, or theycan modify breast cell prolifera-
tion by affecting the intricate balance
between keyhormonal metabolites that influ-
ence parenchymal growth factors in other
ways. Some studies have found that exposing
human breastcancercells that areERpositive
to lipophilic organochlorine compounds
increases 16-OHEI and suppresses 2-OHEI
(36), as do known mammary carcinogens
such as dimethylbenzanthracene.
Concerninggeneticpaths, xenohormones
can cause structural or functional damage to
DNA (37). Functional damage can affect
processes ofcell growth, the abilityoftumor-
suppressor genes to restrain malignant
growth, and the expression oftelomerase to
overcome cellular senescence. Such damage
impedes critical cell repair systems, hinders
recognition of aberrant cells, and allows the
accumulation of harmful mutations.
Structural damage to DNA can occur from
genotoxic agents and from free radical or
redox cycling ofharmful xenoestrogens that
Bifnctonal pathwaysto breastcancer
o/ \7
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Figure 4. Bifunctional pathways to breast cancer. Abbreviations: E2, 17p-estra-
diol; E1, estrone; OHE1, hydroxyestrone; ER, estrogen receptor. In the bifunc-
tional pathway, the E2 metabolites affect cell proliferation and breast cancer
development either directly via receptor-independent mechanisms involving
structural/functional alterations in DNA, or indirectly via receptor-dependent
mechanisms involving phenotypic growth regulation. Both mechanisms even-
tually upregulate aberrant proliferation and development of breast cancer(37).
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produce reactive oxygen species. This redox
cycling yields high rates of radical-induced
DNA damage, including 8-hydroxyguanine
and adenine adducts, apurinic sites, or loss of
ring opening products (e.g., 2,6-diamino-4-
hydroxy-5-formamidopyrimidine) (38,39).
Womenwith breast cancerhave been report-
ed to have significandy higher rates ofsuch
radical-induced damage than do women
without thedisease (40).
Not all xenohormones disrupt normal
endocrine functioning or damage DNA.
Many are "good" xenoestrogens that bind
stronglywith the ERand appear to have pro-
tective effects. Several ofthese are found in
plants, e.g., daidzein, genistein, isoflavonoids,
as well as in fish oil (41-43). Some ofthem
appear to serve as antioxidants. Certain good
xenoestrogens inhibitangiogenesis orprotease
or kinase activity. In this manner they can
reduce the propensity ofaberrant breast cells
to proliferate, increase DNA repair, or pro-
duce otherchanges in thegenetic orhormon-
al microenvironments that alter malignant
progression (44).
Unexplained Patterns of
Breast Cancer
Our proposed conceptual framework can
partly account for the observed temporal
changes in some established risk factors for
breast cancer, such as the decline in age at
menarche over the last half-century. It is
possible that this decline could reflect
changes in both vulnerability and con-
tributing factors. In part, increased total
caloric intake in the diet has resulted in girls
accumulating proportionally more body fat.
Fat is a direct source ofestrogens earlier in
life. Those who are heavier earlier in life
will experience menses and their breasts will
begin developing at earlier ages. In addi-
tion, the extensive use ofgrowth hormones,
including diethylstilbestrol and other estro-
genic compounds, in domestic animal
products and the bioaccumulation of such
xenohormones as organochlorine pesticides
may also contribute to early menarche and
elevate circulating levels ofhormones.
Factors may contribute to breast cancer
by impairing the function oftumor-suppres-
sor genes such as p53 expression or by
impeding the ability ofproteins such as tyro-
sine kinase and protein kinase C functions
(45) to detoxify and excrete carcinogens. An
expanding scientific literature indicates that
prostaglandin levels are higher in cancerous
tissue than in normal tissue (46). Cancer of
the breast forms more prostaglandins than
normal breast tissue (47). Up regulation of
the cyclooxygenases (Cox-1 and Cox-2) cat-
alyzes theformation ofprostaglandins, which
in turn have multiple effects that favor car-
cinogenesis. Contributing factors that inhibit
Cox activity reduce the risk ofcolon, breast,
and lung cancer in animals and humans.
Prostaglandins such as PGF 2 and PGE 2 are
important factors during fetal development,
ovulation, and luteinization. Contributing
factors can convert procarcinogens to car-
cinogens via Cox-mediated metabolism of
arachidonic acid.
Because carcinogens such as benzopy-
rene induce Cox-2, these maybe important
for the development of breast cancer as
well. Overexpression of Cox-2 inhibits
apoptosis and enhances invasiveness of
malignant cells. Young women exposed to
agents that exacerbate such overexpression
are likely to be at increased risk for cancer.
Thus, it is logical to expect that those indi-
viduals with inherited or environmentally
increased levels of carcinogen-activating
enzymes such as Cox-2 will have enhanced
cancer vulnerability (48), while those with
lower levels will have reduced risk (49). In
addition, decreased dietary intake of the
natural Cox-2 inhibitors such as soy
isoflavones, curcumin, and retinoid is a
probable vulnerability factor for the devel-
opment ofbreast cancer.
The framework we offer can also
account for differences in rates of breast
cancer in some areas. Lower rates ofbreast
cancer have consistently been found in
women living in Asian countries, although
rates have increased recently (50).
Pollution in this region is not known to be
particularly low; in fact levels are consider-
ably elevated in China (51). But diets have
traditionally been rich in protective factors
such as soy products, fish, and vegetables
and low in animal dairy products that can
concentrate some contaminants. These
protective factors may account for the rela-
tively low rates of breast cancer and other
hormonally mediated diseases in Asian
women (50).
Inconsistent Results
Recent human studies have focused on
assessing the impact of organochlorine
compounds and have not addressed the
broad array of other suspect xenohor-
mones, many of which leave no biologic
markers, such as benzo[a]pyrene, some
plastics, and fuels. Nor have protective fac-
tors such as genistein and other isoflavones
been widely studied. Organochlorines have
been studied largely because these com-
pounds are persistent and can be measured
years after exposures have occurred. Studies
of these lipophilic compounds have pro-
duced inconsistent results. Results ofsome
of the early studies on organochlorine
residues tended to be positive, with higher
levels ofpolychlorinated biphenyls (PCBs)
and dichlorodiphenyldichloroethylene
(DDE), either in the blood or in adipose
tissue, found among women with breast
cancer than in controls (52,53). In addi-
tion, nested case-control prospective stud-
ies in this field have tended to yield posi-
tive results, especially those that have
looked at ER positive cases (54). Thus, a
small case-control study in Canada found
that women with elevated levels of DDE
had 8.9 times the risk of ER positive dis-
ease than did women with relatively lower
levels of this metabolite (54). ER positive
cases appear to be increasing overall in
women over 60 years of age, according to
one report from California (55). In some
studies, negative results were also described
for the total cancer study population (56)
or for specific subgroups of breast cancer
subjects, such as Asian women (57).
Three recent case-control studies
(56,58,59) oforganochlorine residues have
reported that when first diagnosed, women
with breast cancer actually have lowerlevels
of these compounds in their bodies com-
pared with cases that do not have these dis-
eases. These studies could not examine the
role of exposures during critical windows
earlier in life, but looked only at residues
remaining after the disease was expressed.
In all ofthese studies, levels ofthese conta-
minants measured after the disease has
been detected are severalfold lower than
those reported three decades earlier, indi-
cating the success of programs to reduce
the use of these materials (1). Negative
studies should be considered separately in
terms ofthe regions involved and in terms
ofthe compounds measured.
In two of these studies, which were
conducted outside the United States
(56,59), the authors have indicated that a
majority of the cases were stage II or III
when sample collection was undertaken. In
these circumstances, preclinical disease may
have altered lipid metabolism, which could
account for the fact that these patients
tended to have lower levels of some
organochlorine compounds. One of the
studies, which was conducted in Germany,
the Netherlands, Northern Ireland,
Switzerland, and Spain, found significantly
higher means of DDE in controls than in
cases (59); the OR comparing the highest
to the lowest tertiles of DDE indicated a
reduced risk for the most highly exposed
subjects. Results are less clear in the other
study (61), which was conducted in
Mexico, a country where DDT is still in
use. The arithmetic and geometric means
of DDE were somewhat higher among
cases than among controls; but this finding
was not statistically significant. However,
reduced ORs were found when the highest
and lowest tertiles were compared (56).
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In the United States, a recent nested
case-control study of the Nurses' Health
Study (58) examined 240 cases, 200 of
which involved invasive disease. Samples
obtained in the 2 years before diagnosis
showed relativelylowlevels ofDDE metabo-
lites in this group, with levels being six times
lower than those found in U.S. women in
the 1970s (58). As with the recent foreign
studies, it is undearwhether these lower lev-
els in cases are a consequence ofthe disease
because blood was analyzed when the cancer
process had been underway for periods ofup
to a decade or more. Also, datawere not col-
lected on the role ofprotective factors such
as natural Cox-2 inhibitors and protective
phytoestrogens, such as those found in soy
and fish oil, nor was information obtained
on possible exposures earlier in life.
Moreover, residues ofDDE measured in the
plasma did not show the same estrogenic
activity as the parent mixtures. In fact, DDE
acts primarily as an antiandrogen (60). The
most highly estrogenic contaminants cannot
bedetectedyears afterexposure.
A more recent report from this same
research group used a prospective design
and confirmed that early exposures to
growth factors can be significant, especially
for premenopausal causes of breast cancer.
This new study found that premenopausal
cases ofbreast cancer with the highest levels
ofinsulin-like growth factor-1 as measured
4 years or more before diagnosis had nearly
a sevenfold greater risk of breast cancer
compared to thosewithout the disease (61).
This finding indicates the importance of
looking at a broad array ofpotential protec-
tive and disruptive factors, as well as the
value ofconducting longer term prospective
studies thatpermit their identification.
Studies that consider current levels of
metabolites ofpesticides in cancer patients
have been described as analogous to "looking
under the nearest lamppost for lost keys
because that is where there is light" (60).
Two critical questions must be raised: What
were exposures toxenohormones duringcrit-
ical windows ofdevelopment, including the
prenatal and prepubescent periods, andwhat
was the lifetime exposure to hormonally
active parent compounds? Studies that look
at contemporaneous measures oflipophilic
metabolites of organochlorine compounds
cannot resolve these questions. Moreover,
measures of total PCBs cannot distinguish
between active materials that are highly
estrogenic and those which are antiestro-
genic, and analytic studies ofexposure need
to bestandardized forlipidadjustment (62.
Need for Longer Term Studies
Limited epidemiological studies have been
conducted on the roleofharmfuil orprotective
xenohormonal factors throughout the life
cycle. No long-term comprehensive studies
have yet been conducted or planned on
large populations involving prenatal risk fac-
tors for breast cancer. In addition, biomark-
ers or metabolites ofmany quickly metabo-
lized suspected agents such as some compo-
nents ofplastics, fuels, and aromatic materi-
als cannot be directly measured in women
long after exposure has ceased. Studies that
lookatcurrent levels oflipophilic residues in
cases ofbreast cancer compared to controls
cannot resolve the issue of whether past
exposures play a role in the development of
the disease. The process of cancer alters
metabolism in ways that are not well under-
stood. Given the complex and competing
roles of xenohormones, only long-term
prospective studies that cover two genera-
tions will be able to resolve the issue ofthe
relative roles ofprenatal, prepubescent, and
subsequent exposures to harmful and benefi-
cial xenohormones. Especially as potent
forms of materials are excreted, it will be
very important to obtain residues over the
natural lifetime. Thus, the relative role of
harmful or protective xenohormones and
other factors such as Cox-2 inhibitors in
affecting breast cancer vulnerability and in
directly causing the disease is a matter that
can only be resolved by studies that collect
tissue foranalyses through two generations.
Significant and unexplained elevated
rates ofbreast cancer have been found across
the United States, in places as diverse as
Cape Cod, Massachusetts, and central
Illinois. A recent report from San Francisco,
California, like an earlier one from Long
Island, New York, found that differences in
the prevalence ofso-called risk factors could
theoretically account for all ofthe differences
in the rate ofbreast cancer in that area (63).
This study employed no individual mea-
sures, but modeled risk factors obtained in
previous surveys of populations at risk of
ovarian cancer compared to the population
of San Francisco. In contrast, a national
study ofbreast cancer mortality found that
known risk factors accounted for only about
half of the overall regional excess (64).
Historically breast cancer incidence is about
four- to sevenfoldhigher in the United States
than in Asia. The risk of breast cancer
increases when women migrate from those
countries to the West. Those Asian-
American women whose grandparents were
born in America have 60% greater risk of
breast cancer than those whose grandparents
were born in Asia. Immigrants living in the
West for a decade or longer have a risk of
breast cancer 80% higher than more recent
immigrants (50). The notion that there is
something protective about being Asian is
also borne out by a study that found no
increased risk from elevated organochlorines
in Asian-American women, but a two- to
threefold risk in white and African-
American women (57.
Basic Research Issues
We need to ask a number ofbasic research
questions based on this proposed rethinking
of risk factors. Why do girls who are taller
and heavier at earlier ages have a greater rate
ofbreast cancer? Could growth hormones in
chickens, eggs, and dairy and meat products
be involved in addition to greater amounts of
calories overall? Why do women who lactate
have a reduced risk ofpremenopausal breast
cancer? Could lactation rid the body of
potentially harmful, cancer-causing lipophilic
agents in the mostly fatty breast tissue? For
postmenopausal women, could cumulative
buildup ofharmful xenoestrogens effectively
void the added protection lactation provides
for premenopausal women? Why do women
who regularlyconsumealcohol have an excess
risk ofbreast cancer? Why does alcohol con-
tribute so dramatically to circulations ofhor-
mones in the blood? Why do women who
exercise regularly have less breast cancer?
Could their bodies contain lower levels of
hormones, proportionally less fat, and less
contaminants in fat that damage the breasts?
Does a diet high in beneficial xenohormones,
such as genistein and omega-3-fatty acids,
protect againstbreastcancerinAsian women?
Would supplements or diets high in these
foods preventbreastcancer? Does exposure to
electromagnetic fields lower melatonin,
which is a natural suppressor ofbreast cancer
cell growth (65)? Do combustion by-prod-
ucts from fossil fuels (66) or from uncon-
trolled incineration ofmedical waste play any
role in the increased rates ofbreast cancer in
theurbanenvironment (67)?
Public Policy Questions
It has been sardonically noted that one out
of every four breast cancer cases among
white women could be prevented if all
white women had children before age 20,
underwent menarche after age 14, had par-
ents with no genetic or cultural predisposi-
tions to the disease, and had no benign
breast conditions detected by a biopsy (12).
In fact, most well-established risk factors for
breast cancer cannot be changed in the pre-
sent generation. Many of the risk factors
involve exposures and circumstances that
arise early in life; others entail matters over
which women have little or no control as
adults, such as the onset of menopause.
Current proposed interventions to reduce
breast cancer mainly focus on changing
individual behaviors, including such self-
imposed restrictions as lifelong administra-
tion of pharmaceutical agents or radical
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changes in diet, exercise regime, or repro-
ductive behavior. However, some of the
causes ofbreast cancer and related diseases
can only be controlled by social and politi-
cal action aimed at reducing the produc-
tion, use, transport, and disposal of agents
that directly or indirectly affect breast can-
cer risks.
The identification of contributing and
vulnerability risk factors will provide a key
missing component forfostering the promo-
tion of policies that require public policy
interventions. The public and private sectors
could, for example, devise policies to pre-
vent, restrict, or reduce exposures to agents
in the household, workplace, and general
environment that extend the duration and
onset ofbreast growth or alter the hormonal
environment. For these policies to succeed,
experimental screening tests to identify
xenohormones and other disruptive agents
merit high priority. Once such test systems
are in place, procurement policies as well as
policies regarding workplace safety, educa-
tion, and training and international trade
can be modified to encourage the use of
materials found to be less likely to alter hor-
monal metabolism and extendcell growth.
Where there are significant risks ofdamage to
the public health, we should be prepared to take
action to diminish those risks evenwhen the sci-
entific knowledge is not conclusive, if the bal-
ance oflikelycosts and benefits justifies it [from
Horton (68].
The remaining central question for public
policy is what risk factors give rise to 19 out
of20 cases ofbreast cancer. For more than
30 years, studies have repeatedly confirmed
unmodifiable risk factors. These account for
less than halfofall cases. Probing for what
avoidable causes lurkbehind breast cancer in
San Francisco, Cape Cod, or anywhere else
will be vital to solving the growing puzzle
surrounding the disease and reducing its
burden further.
For further information, see the World
Resources InstituteWebsite (6S1l.
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